Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$200.61 USD
-1.07 (-0.53%)
Updated Dec 4, 2023 04:00 PM ET
After-Market: $200.64 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
CRL 200.61 -1.07(-0.53%)
Will CRL be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRL
Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe
Charles River (CRL) Backs the Quest to Cure SPG56 via New Deal
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Charles River (CRL) Widens CliniPrime GMP Suite With New Launch
Charles River (CRL) to Advance AI Drug Discovery With New Pact
Charles River's (CRL) Q3 Earnings Beat, Margins Decline
Other News for CRL
Creightons swings to half-year profit on cost-cutting measures
Insider Sell: EVP Joseph Laplume Sells Shares of Charles River Laboratories International Inc (CRL)
CRL Crosses Above Key Moving Average Level
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories to Present at Evercore ISI Investor Conference